October 20, 2026
Law360 Healthcare Authority looks at the Second Circuit's denial of a drugmaker's request for full review of expert testimony for plaintiffs in a case alleging Tylenol causes autism, the preliminary approval of a $400 million settlement between Sandoz and a coalition of states in generic drug price-fixing litigation, and other legal news from the past week.
October 16, 2026
The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.
September 11, 2026
Tylenol maker Kenvue and several retailers have urged the Second Circuit to revisit its decision overturning a district court's exclusion of expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD, saying the appeals court improperly restricted the trial court's "gatekeeping role."
July 24, 2026
In one of the most-watched cases for product liability so far this year, the U.S. Supreme Court ruled that failure-to-warn claims about the alleged cancer risks of Monsanto's widely used pesticide Roundup are barred by federal law. Social media titans were also rocked by the first verdicts delivered in cases alleging mental health harms to youth.
July 13, 2026
The Second Circuit said Monday that a lower court had wrongly excluded plaintiffs experts from testifying about an alleged relationship between using Tylenol during pregnancy and autism spectrum disorder and attention-deficit/hyperactivity disorder, although the panel cautioned that the decision was not political or scientific.